Establishment of patient-derived non-small cell lung cancer xenograft models with genetic aberrations within EGFR, KRAS and FGFR1: useful tools for preclinical studies of targeted therapies

Development and characterization of a bladder cancer xenograft model using patient-derived tumor tissue

(2013) Bumsoo Park et al.   CANCER SCIENCE

Translating the Therapeutic Potential of AZD4547 in FGFR1-Amplified Non-Small Cell Lung Cancer through the Use of Patient-Derived Tumor Xenograft Models

(2012) J. Zhang et al.   CLINICAL CANCER RESEARCH

Patient-derived tumour xenografts as models for oncology drug development

(2012) John J. Tentler et al.   Nature Reviews Clinical Oncology

Lung cancer: New biological insights and recent therapeutic advances

(2011) Suresh S. Ramalingam et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)

(2011) Masahiro Fukuoka et al.   JOURNAL OF CLINICAL ONCOLOGY

Inhibitor-Sensitive FGFR1 Amplification in Human Non-Small Cell Lung Cancer

(2011) Amit Dutt et al.   PLoS One

Vandetanib Improves Anti-Tumor Effects of L19mTNF  in Xenograft Models of Esophageal Cancer

(2010) M. Crescenzi et al.   CLINICAL CANCER RESEARCH

Comparative Profiling of the Novel Epothilone, Sagopilone, in Xenografts Derived from Primary Non-Small Cell Lung Cancer

(2010) S. Hammer et al.   CLINICAL CANCER RESEARCH

Assessment of the In vivo Antitumor Effects of ENMD-2076, a Novel Multitargeted Kinase Inhibitor, against Primary and Cell Line-Derived Human Colorectal Cancer Xenograft Models

(2010) J. J. Tentler et al.   CLINICAL CANCER RESEARCH

The Ability to Form Primary Tumor Xenografts Is Predictive of Increased Risk of Disease Recurrence in Early-Stage Non-Small Cell Lung Cancer

(2010) T. John et al.   CLINICAL CANCER RESEARCH

Advances in chemotherapy in advanced non-small-cell lung cancer

(2010) Paolo Maione et al.   EXPERT OPINION ON PHARMACOTHERAPY

Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

(2010) Eunice L. Kwak et al.   NEW ENGLAND JOURNAL OF MEDICINE

Frequent and Focal FGFR1 Amplification Associates with Therapeutically Tractable FGFR1 Dependency in Squamous Cell Lung Cancer

(2010) J. Weiss et al.   Science Translational Medicine

A Primary Xenograft Model of Small-Cell Lung Cancer Reveals Irreversible Changes in Gene Expression Imposed by Culture In vitro

(2009) V. C. Daniel et al.   CANCER RESEARCH

Patient-derived xenografts of non-small-cell lung cancer: a pre-clinical model to evaluate adjuvant chemotherapy?☆

(2009) Johannes Merk et al.   EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY

Recent advances of novel targeted therapy in non-small cell lung cancer

(2009) Jed A Katzel et al.   Journal of Hematology & Oncology

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

(2009) Tetsuya Mitsudomi et al.   LANCET ONCOLOGY

Establishment of Patient-Derived Non-Small Cell Lung Cancer Xenografts as Models for the Identification of Predictive Biomarkers

(2008) I. Fichtner et al.   CLINICAL CANCER RESEARCH

METgene amplification orEGFRmutation activate MET in lung cancers untreated with EGFR tyrosine kinase inhibitors

(2008) Takafumi Kubo et al.   INTERNATIONAL JOURNAL OF CANCER

BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

(2008) D Li et al.   ONCOGENE

The use of xenograft models for the selection of cancer treatments with the EGFR as an example

(2007) Teresa Troiani et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY